Drug makers do not list bad breath itself as an official side effect
10.3390/antiox9040344 57 HuangY.ZangY.ZhouL.GuiW.LiuX.ZhongY
Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and [PMID: 41651376] Laboratory literature summary: Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements
Despite its favorable safety profile, patients can encounter rare but serious side effects of Semaglutide
And, so far, while quality and safety inspections and enforcement typical among compounders are occurring with compounders of GLP-1 products, we have not seen evidence publicly that the FDA is taking action specifically against the practice of compounding GLP-1 products that are no longer in shortage as products that are essentially a copy of the FDA-approved products
Int J Life Sci Pharma Res 13(5):P25P50 Makrilakis K (2019) The role of DPP-4 inhibitors in the treatment algorithm of type 2 diabetes mellitus: when to select, what to expect
